Qufora: Taking due diligence from “check-list” to value creation

Type: Transaction support
Timeline: 2024

About Qufora: Qufora is a specialised medical device company based in Denmark focused on developing and manufacturing innovative bowel management solutions aimed at improving the quality of life for individuals with chronic bowel disorders.

Our work: During 2024, Raison conducted due diligence of Qufora on behalf of the investor (Impilo) focused on assessing the company’s health impact potential, its material ESG risks and alignment with the investor’s minimum requirements.

Our contribution:

• Delivered a clear value creation plan through a Qufora Health Impact Thesis (HIT) focused on enhancing quality and availability of care for people suffering from bowel disfunctions (see Impilo 2024 annual report p. 14)
• Created a robust baseline for assessing company maturity and gaps on material ESG issues to help define priorities and resources post-investment.